Generating and managing Intellectual Property (IP) is a priority and strong competency at Lumeda, in which the two company founders are inventors on over 85 issued patents with numerous patents pending.

Our DigiLum™ product is protected under an IP portfolio that includes both internally generated and externally licensed IP. Lumeda has secured a globally exclusive license from Roswell Park Cancer Institute for patents covering core medical devices, PDT systems, and therapeutic delivery methods.

The company has generated 26 invention disclosures of which 11 have been processed into PCT patent applications that cover optical devices, instrumentation, and machine-learning algorithms incorporated in the DigiLum™ system, as well as use of the system in combination with photosensitizer agents, including minimally invasive procedures.